Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Consolidated Net Income (2016 - 2026)

Corcept Therapeutics' Consolidated Net Income history spans 16 years, with the latest figure at -$31.8 million for Q1 2026.

  • On a quarterly basis, Consolidated Net Income fell 254.8% to -$31.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $47.3 million, a 64.67% decrease, with the full-year FY2025 number at $99.7 million, down 29.43% from a year prior.
  • Consolidated Net Income hit -$31.8 million in Q1 2026 for Corcept Therapeutics, down from $24.3 million in the prior quarter.
  • Over the last five years, Consolidated Net Income for CORT hit a ceiling of $47.2 million in Q3 2024 and a floor of -$31.8 million in Q1 2026.
  • Historically, Consolidated Net Income has averaged $24.5 million across 5 years, with a median of $27.5 million in 2023.
  • Biggest five-year swings in Consolidated Net Income: soared 89.07% in 2023 and later crashed 254.8% in 2026.
  • Tracing CORT's Consolidated Net Income over 5 years: stood at $16.6 million in 2022, then skyrocketed by 89.07% to $31.4 million in 2023, then decreased by 2.06% to $30.7 million in 2024, then dropped by 21.0% to $24.3 million in 2025, then plummeted by 230.77% to -$31.8 million in 2026.
  • Business Quant data shows Consolidated Net Income for CORT at -$31.8 million in Q1 2026, $24.3 million in Q4 2025, and $19.7 million in Q3 2025.